Pfizer Inc.’s extended-release opioid Troxyca ER (oxycodone/naltrexone) received positive advisory committee recommendations June 8, but they came with a call for FDA to make decisions about abuse-deterrent claims that are informed by post-marketing data.
One member of the joint Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management advisory committees even suggested...